Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

View Full Paper
Ask AI
Bookmark
Share

Authors

LALionel AdèsAGAlice GarnierUPUwe Platzbecker

Discussion

Loading...

Member takes

Overview

Phase II trial shows limited efficacy of imetelstat in MDS and AML patients after HMA failure, implying urgent need for new treatments.

Key Points

  • The aim was to evaluate the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML after failing HMA-based therapy.
  • Multicenter phase II IMpress trial
  • Evaluated imetelstat sodium in patients refractory or relapsing after HMA
  • Primary endpoint was overall response rate after four months
  • Dosing amended to biweekly in response to lack of efficacy
  • 6/23 patients in the second cohort reached the primary endpoint visit after treatment
  • Median overall survival was 119 days for the first cohort and 102 days for the second
  • 29 serious adverse events reported, with febrile neutropenia being the most common
  • No new safety signals associated with increased drug exposure showed

Cite This Study

Adès et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d882https://doi.org/10.1182/blood-2025-5155
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower‐Risk Myelodysplastic Syndromes2025
  2. 2Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat2026 · 1 citations
  3. 3Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study2026 · 1 citations
  4. 4Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis2025 · 2 citations
  5. 5Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.2024